Designation of Phenethyl Halides as List I Chemicals
DEA proposes to designate phenethyl halides as List I chemicals under the CSA, imposing new registration, recordkeeping, and reporting requirements on businesses that handle these chemicals.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies that manufacture, distribute, import, or export phenethyl halides. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective date of final rule (typically 30-60 days after publication); comment period ends 60 days from July 9, 2026.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Phenethyl halides will be classified as List I chemicals, requiring DEA registration, maintenance of records, and reporting of suspicious orders.
Who it affects
Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies that manufacture, distribute, import, or export phenethyl halides.
What you must do
Review current chemical inventory for phenethyl halides; if handled, apply for DEA List I chemical registration and establish compliance protocols.
Deadline
Effective date of final rule (typically 30-60 days after publication); comment period ends 60 days from July 9, 2026.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order